Structure and function studies of glucagon‐like peptide‐1 (GLP‐1): the designing of a novel pharmacological agent for the treatment of diabetes
Citations Over TimeTop 18% of 2005 papers
Abstract
Glucagon-like peptide-1 (GLP-1) is a proglucagon-derived peptide secreted from gut endocrine cells in response to nutrient ingestion. The multifaceted actions of GLP-1 include the following: (1) the stimulation of insulin secretion and of its gene expression, (2) the inhibition of glucagon secretion, (3) the inhibition of food intake, (4) the proliferation and differentiation of beta cells, and (5) the protection of beta-cells from apoptosis. The therapeutic utility of the native GLP-1 molecule is limited by its rapid enzymatic degradation by a serine protease termed dipeptidyl peptidase-IV (DPP-IV). The present article reviews the research studies aimed at elucidating the biosynthesis, metabolism, and molecular characteristics of GLP-1 since it is from these studies that the development of a GLP-1-like pharmacological agent may be derived.
Related Papers
- → Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2(2003)215 cited
- → Fermentable Dietary Fiber Increases GLP-1 Secretion and Improves Glucose Homeostasis Despite Increased Intestinal Glucose Transport Capacity in Healthy Dogs(1998)184 cited
- → Apple and banana displayed better inhibition of dipeptidyl peptidase IV activity than vildagliptin(2018)1 cited
- → Biological actions of glucagon-like peptide(GLP)-2 revealed — how pluripotential is the glucagon gene?(2009)3 cited
- → Glucagon-like Peptide 2 (GLP-2)(2004)